LNTH · Lantheus Holdings, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $377.33M | - | $384.01M | $378.05M | $372.76M | - | $378.73M | $394.09M | $369.98M | - |
| Cost of Revenue | $146.41M | - | $161.65M | $137.03M | $135.06M | - | $136.61M | $138.32M | $128.13M | - |
| Gross Profit | $230.92M | - | $222.37M | $241.01M | $237.70M | - | $242.13M | $255.77M | $241.85M | - |
| R&D | $39.38M | - | $48.02M | $45.49M | $36.31M | - | $24.15M | $60.60M | $48.02M | - |
| SG&A | $57.53M | - | $81.90M | $66.52M | $56.82M | - | $40.52M | $47.41M | $47.90M | - |
| Total Operating Expenses | - | - | - | - | - | - | - | - | - | - |
| D&A | - | - | - | - | - | - | - | - | - | - |
| Operating Income | $81.33M | - | $43.62M | $87.97M | $102.07M | - | $133.74M | $102.73M | $106.64M | - |
| Interest Expense | $4.86M | - | $4.95M | $4.92M | $4.86M | - | $4.90M | $4.93M | $4.86M | - |
| Income Tax | $37.99M | - | $14.61M | $25.76M | $23.58M | - | $45.02M | $22.30M | $40.20M | - |
| Net Income | $118.42M | - | $27.77M | $78.75M | $72.94M | - | $131.09M | $62.07M | $131.07M | - |
| EPS - Basic | $1.83 | - | $0.41 | $1.15 | $1.06 | - | $1.89 | $0.89 | $1.91 | - |
| EPS - Diluted | $1.80 | - | $0.41 | $1.12 | $1.02 | - | $1.79 | $0.88 | $1.87 | - |
Balance Sheet
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $498.58M | $359.12M | $382.01M | $695.57M | $938.53M | $912.81M | $866.39M | $757.02M | $718.28M | $713.66M |
| Accounts Receivable | $355.67M | $358.64M | $351.38M | $336.58M | $348.75M | $321.26M | $329.34M | $372.29M | $337.39M | $284.29M |
| Inventory | $61.34M | $64.67M | $62.04M | $62.16M | $69.13M | $68.03M | $70.83M | $70.52M | $69.76M | $64.03M |
| Accounts Payable | $45.88M | $42.91M | $66.30M | $40.89M | $44.87M | $34.56M | $44.91M | $49.77M | $37.52M | $41.19M |
| Current Assets | $942.29M | $899.96M | $925.09M | $1.20B | $1.42B | $1.33B | $1.30B | $1.23B | $1.15B | $1.09B |
| Total Assets | $2.35B | $2.23B | $2.28B | $2.12B | $2.06B | $1.98B | $2.05B | $1.94B | $1.83B | $1.65B |
| Current Liabilities | $333.17M | $333.42M | $346.84M | $280.13M | $248.00M | $240.53M | $784.08M | $263.29M | $237.20M | $187.35M |
| Long-term Debt | - | - | - | - | - | - | - | - | - | - |
| Total Liabilities | $1.13B | $1.14B | $1.16B | $949.29M | $891.03M | $892.33M | $869.92M | $913.15M | $885.79M | $835.26M |
| Stockholders' Equity | $1.21B | $1.09B | $1.12B | $1.17B | $1.16B | $1.09B | $1.18B | $1.03B | $945.54M | $815.89M |
| Retained Earnings | $797.92M | $679.50M | $625.42M | $597.64M | $518.89M | $445.94M | $457.74M | $326.64M | $264.57M | $133.50M |
Cash Flow
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | $125.13M | - | - | - | $107.56M | - | - | - | $127.24M | - |
| Investing Cash Flow | $25.99M | - | - | - | ($63.72M) | - | - | - | ($106.53M) | - |
| Financing Cash Flow | ($11.62M) | - | - | - | ($18.22M) | - | - | - | ($16.84M) | - |
| CapEx | - | - | - | - | - | - | - | - | - | - |
| Free Cash Flow | - | - | - | - | - | - | - | - | - | - |
Ratios
| Metric | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | 61.2% | - | 57.9% | 63.8% | 63.8% | - | 63.9% | 64.9% | 65.4% | - |
| Operating margin | 21.6% | - | 11.4% | 23.3% | 27.4% | - | 35.3% | 26.1% | 28.8% | - |
| EBITDA margin | - | - | - | - | - | - | - | - | - | - |
| Net margin | 31.4% | - | 7.2% | 20.8% | 19.6% | - | 34.6% | 15.8% | 35.4% | - |
| Free cash flow margin | - | - | - | - | - | - | - | - | - | - |
| FCF / Net income | - | - | - | - | - | - | - | - | - | - |
| R&D / Revenue | 10.4% | - | 12.5% | 12.0% | 9.7% | - | 6.4% | 15.4% | 13.0% | - |
| SG&A / Revenue | 15.2% | - | 21.3% | 17.6% | 15.2% | - | 10.7% | 12.0% | 12.9% | - |
| Effective tax rate | 24.3% | - | 34.5% | 24.6% | 24.4% | - | 25.6% | 26.4% | 23.5% | - |
| Return on assets | 5.0% | - | 1.2% | 3.7% | 3.5% | - | 6.4% | 3.2% | 7.2% | - |
| Return on equity | 9.8% | - | 2.5% | 6.7% | 6.3% | - | 11.1% | 6.0% | 13.9% | - |
| Return on invested capital | - | - | - | - | - | - | - | - | - | - |
| Liquidity | ||||||||||
| Current ratio | 2.83 | 2.70 | 2.67 | 4.29 | 5.74 | 5.52 | 1.65 | 4.68 | 4.84 | 5.80 |
| Quick ratio | 2.64 | 2.51 | 2.49 | 4.07 | 5.46 | 5.23 | 1.56 | 4.41 | 4.55 | 5.45 |
| Cash ratio | 1.50 | 1.08 | 1.10 | 2.48 | 3.78 | 3.80 | 1.10 | 2.88 | 3.03 | 3.81 |
| Leverage | ||||||||||
| Debt / Equity | - | - | - | - | - | - | - | - | - | - |
| Debt / Assets | - | - | - | - | - | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest coverage | 16.7x | - | 8.8x | 17.9x | 21.0x | - | 27.3x | 20.8x | 21.9x | - |
| Equity multiplier | 1.94 | 2.04 | 2.03 | 1.81 | 1.77 | 1.82 | 1.74 | 1.89 | 1.94 | 2.02 |
| Liabilities / Assets | 0.48 | 0.51 | 0.51 | 0.45 | 0.43 | 0.45 | 0.42 | 0.47 | 0.48 | 0.51 |
| Efficiency | ||||||||||
| Asset turnover | 0.16 | - | 0.17 | 0.18 | 0.18 | - | 0.18 | 0.20 | 0.20 | - |
| Inventory turnover | 2.39 | - | 2.61 | 2.20 | 1.95 | - | 1.93 | 1.96 | 1.84 | - |
| Days sales outstanding | 344d | - | 334d | 325d | 341d | - | 317d | 345d | 333d | - |
| Days inventory outstanding | 153d | - | 140d | 166d | 187d | - | 189d | 186d | 199d | - |
| Days payable outstanding | 114d | - | 150d | 109d | 121d | - | 120d | 131d | 107d | - |
| Cash conversion cycle | 383d | - | 324d | 382d | 407d | - | 387d | 400d | 425d | - |
| Valuation | ||||||||||
| P / E | 42.1x | - | 125.1x | 73.1x | 95.7x | - | 61.3x | 91.2x | 33.3x | - |
| P / B | 4.1x | - | 3.1x | 4.9x | 6.0x | - | 6.8x | 5.5x | 4.6x | - |
| P / S | 13.2x | - | 9.0x | 15.2x | 18.7x | - | 21.2x | 14.4x | 11.8x | - |
| EV / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Growth | ||||||||||
| Revenue growth (YoY) | 1.2% | - | 1.4% | -4.1% | 0.8% | - | 18.4% | 22.5% | 23.0% | - |
| Revenue CAGR (3y) | 7.9% | - | 17.1% | 19.1% | 21.3% | - | 54.8% | 57.4% | 58.7% | - |
| Revenue CAGR (5y) | 32.5% | - | 34.1% | 41.8% | 32.7% | - | 34.6% | 35.7% | 33.7% | - |
| Gross profit growth (YoY) | -2.9% | - | -8.2% | -5.8% | -1.7% | - | 21.1% | 26.2% | 213.8% | - |
| Operating income growth (YoY) | -20.3% | - | -67.4% | -14.4% | -4.3% | - | 19.0% | -17.2% | - | - |
| Net income growth (YoY) | 62.3% | - | -78.8% | 26.9% | -44.3% | - | -0.7% | -34.1% | - | - |
| EPS growth (YoY) | 76.5% | - | -77.1% | 27.3% | -45.5% | - | -4.8% | -33.8% | - | - |
| EPS CAGR (3y) | - | - | -21.9% | 22.5% | 18.7% | - | - | - | 143.2% | - |
| EPS CAGR (5y) | 69.1% | - | - | - | 66.4% | - | 71.7% | 40.6% | 49.5% | - |
| FCF growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | 4.1% | 0.2% | -5.1% | 13.6% | 23.1% | 33.4% | 68.8% | 85.8% | 112.2% | 82.5% |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2025-12-31.
Product / service
$4.57B totalProduct$1.51B · 33.0%
PYLARIFY$989.12M · 21.7%
Radiopharmaceutical Oncology$989.12M · 21.7%
Total Precision Diagnostics$493.11M · 10.8%
Definity$330.25M · 7.2%
Techne Lite$86.80M · 1.9%
Strategic Partnerships And Other$59.38M · 1.3%
Neuraceq$51.45M · 1.1%
Licenseand Royalty Revenues$34.04M · 0.7%
Other Precision Diagnostics$24.62M · 0.5%
Geographic
$1.54B totalUS$1.46B · 94.6%
Non Us$82.73M · 5.4%
Peer comparison
Same SIC group: In Vitro & In Vivo Diagnostic Substances
Comparing Lantheus Holdings against the 5 most active filers in the same SIC group.